关键词：类风湿关节炎；药物；慢性炎症性；自身免疫性疾病；遗传；环境因素
摘 要：RA is a chronic inflammatory autoimmune disease seen in people aged between 30 and 60 years. The symptoms of the disease appear slowly, with mild pain around the joints coupled with stiffness and fatigue. In the later stages, it causes inflammation of the joints. Genetic and environmental elements are known to contribute to the development of the condition. DMARDs, NSAIDs, corticosteroids, and analgesics are being developed and administered to treat individuals with RA.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

Assumptions

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding RA

Etiology and pathophysiology

Signs and symptoms

Diagnosis

Disease management

Economic burden of RA

Epidemiology

PART 06: Impact of biologics in RA

PART 07: Pipeline portfolio

Novel mechanisms targeted by pipeline candidates

Clinical trials for RA

PART 08: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 09: Market segmentation by drug class

DMARDs

NSAIDs

Corticosteroids

Analgesics

Others

Global DMARDs market

Global NSAIDs market

Global corticosteroids market

Global analgesics market

PART 10: Market segmentation by MOA

TNF inhibitors

IL-1 blockers

JAK inhibitors

Selective costimulation modulators

PART 11: Market segmentation by type of molecule

Biologics

Small molecules

PART 12: Market segmentation by ROA

Oral

Parenteral

Topical

PART 13: Market segmentation by dosage form

Solid

Liquid

Semi-solid

PART 14: Geographical segmentation

RA drugs market in Americas

RA drugs market in US

RA drugs market in EMEA

RA drugs market in Germany

RA drugs market in UK

RA drugs market in Spain

RA drugs market in Italy

RA drugs market in France

Rheumatoid arthritis drugs market in APAC

RA drugs market in Japan

RA drugs market in Australia

RA drugs market in India

RA drugs market in China

PART 15: Key leading countries

PART 16: Market drivers

Growing older population

Market dominance of biologics

Promising drug pipeline

Changing lifestyle patterns

Advances in diagnosis technology

PART 17: Impact of drivers

PART 18: Market challenges

Increasing costs of biologicals

Loss of patent exclusivity of branded therapies

Use of complementary and alternative medicines

(CAMs)

Adverse effects of drugs

Stringent regulations

PART 19: Impact of drivers and challenges

PART 20: Market trends

Emergence of biosimilars

Patient assistance programs

Popularity of off-label and traditional treatment options

Strategic alliances

Increase in public awareness

PART 21: Vendor landscape

Competitive scenario

Market share analysis 2015

AbbVie

Amgen

BMS

F. Hoffmann-La Roche

Johnson & Johnson

Pfizer

Other prominent vendors

PART 22: Appendix

List of abbreviations

PART 23: Explore Technavio